JNJ 64400141

Drug Profile

JNJ 64400141

Alternative Names: Ad26.RSV.preF; JNJ-64400141

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Janssen
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention, In volunteers, In the elderly) in USA (IM) (NCT02926430)
  • 13 Oct 2016 Preclinical trials in Respiratory syncytial virus infections (Prevention, In Volunteers) in USA (IM) (NCT02926430)
  • 13 Oct 2016 Janssen Vaccines & Prevention B.V. plans a phase I trial for Healthy Volunteers (prevention) in USA (NCT02926430)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top